" class="no-js "lang="en-US"> Ankyra Therapeutics - Medtech Alert
Thursday, July 31, 2025
Ankyra Therapeutics | PTF

Ankyra Therapeutics

About Ankyra Therapeutics

Ankyra Therapeutics

Ankyra Therapeutics is a biotechnology company developing a novel approach to treating cancer, designed to expand the therapeutic window of cytokine drugs. Cytokine treatments have shown to be effective in treating cancer, but systemic dosing is limited by broad immune activation and toxicity. Using its proprietary Anchored Immunotherapy Platform, Anykyra has developed methods to localize cytokines specifically and persistently in tumor tissue, creating intense hot spots of inflammation that awaken an anti-tumor immune response. Using its platform, the company is building a pipeline of therapeutics designed to provide prolonged immune activation and potent local and systemic immunity with reduced systemic toxicity.

Related Story

Ankyra Therapeutics Appoints Experienced Financial Executive Stephen Gorgol as Chief Financial Officer

March 22 2023

Ankyra Therapeutics, a biotech company developing targeted immune-activating agents for the treatment of cancer, has […]

Ankyra Therapeutics Appoints Leisha A. Emens, M.D., Ph.D., as Senior Vice President, Translational Research

December 7 2022

Ankyra Therapeutics, a biotech company developing targeted immune-activating agents for the treatment of cancer, today […]